--- title: "Alzheimer's Study Suggests P3 May Be Contributing Factor" url: https://noti.group/alzheimer-s-study-suggests-p3-may-be-contributing-factor/ language: en publisher: "Noti Group" section: "Health" published: 2026-10-14T11:06:19.000Z updated: 2026-10-15T01:36:09.422Z id: c00c8f91-c53a-4a76-826d-2f0a5402f1d8 source: "ScienceDaily Health https://www.sciencedaily.com/releases/2026/10/261013015838.htm" attribution: "Link to https://noti.group/alzheimer-s-study-suggests-p3-may-be-contributing-factor/ and name Noti Group when you quote or summarize this story." --- # Alzheimer's Study Suggests P3 May Be Contributing Factor A new study suggests that another peptide, called P3, may be just as culpable in Alzheimer's disease as amyloid beta, which has been the focus of research for years. Researchers have been focusing on amyloid beta for years in their quest for an effective Alzheimer's treatment, but a new study suggests that another peptide may be just as culpable in the disease. A biochemist at the University of California, Santa Cruz, is now questioning whether this smaller peptide, called P3, has been overlooked for too long. For decades, scientists have invested heavily in developing treatments targeting amyloid beta, which forms toxic deposits in the brain and contributes to Alzheimer's symptoms. However, recent research indicates that P3 may also play a significant role in the disease. This lesser-known peptide can form microscopic clumps and threadlike structures called fibrils, which could contribute to nerve cell damage. Studies have shown that P3 interacts with amyloid beta, potentially influencing how it accumulates in the brain and becomes toxic. This raises the possibility that P3 contributes to Alzheimer's symptoms, forcing researchers to re-evaluate their understanding of the disease. According to experts, P3 may not be as harmless as previously thought. The implications are significant: if P3 is indeed a contributing factor, then current treatments targeting amyloid beta alone may not be effective in preventing or treating Alzheimer's. This could explain why existing treatments have had limited success in combating the disease, which affects millions worldwide and generates enormous costs annually. Alzheimer's is now recognized as the most widespread neurodegenerative disorder globally, affecting approximately 35 million people and causing annual expenses exceeding $800 billion. The number of individuals living with the condition is expected to double by 2050, highlighting the urgent need for new treatments that can effectively combat Alzheimer's symptoms. Despite decades of research into Alzheimer's disease, developing effective treatments has been a daunting task. More than 400 clinical trials have investigated potential Alzheimer's drugs, but most have focused on amyloid beta, a protein fragment that accumulates in the brains of people with the condition. Amyloid beta is derived from a larger protein called Amyloid Precursor Protein (APP), which is embedded in cell membranes. Two enzymes, beta-secretase and gamma-secretase, break down APP into smaller fragments, including amyloid beta peptides of varying lengths. Researchers have concentrated on two specific versions: Aβ40 and Aβ42. Aβ42 has been the focus of particular attention due to its tendency to aggregate and form toxic clumps. As a result, it has remained a central target for Alzheimer's drug development over the years. However, despite this intense focus, existing treatments have only provided temporary relief from symptoms, without slowing or halting disease progression. The current crop of medications includes cholinesterase inhibitors and N-methyl-D-aspartate (NMDA) receptor antagonists, which can temporarily alleviate certain symptoms but do not address the underlying cause of the condition. More recently, antibody treatments such as Lecanemab and Donanemab have been approved to help remove amyloid beta from the brain. Despite these advances, experts argue that the benefits achieved so far are limited, highlighting the need for a fresh approach to understanding the biology of Alzheimer's disease. The process by which Amyloid Precursor Protein is broken down into different peptides has been a key area of study in Alzheimer's research. In one pathway, an enzyme called alpha-secretase acts first, followed by gamma-secretase, resulting in the formation of a peptide known as P3. Researchers have proposed calling this peptide "Amyloid alpha" or A-alpha to distinguish it from amyloid beta and reflect its ability to form aggregates. This nomenclature aims to better understand and track the behavior of P3 in the context of Alzheimer's disease. For years, scientists assumed that P3 was incapable of forming toxic amyloid deposits and would remain soluble in water. However, these assumptions were never thoroughly verified, allowing them to influence research efforts despite being based on incomplete information. A team led by a specialist in peptide chemistry decided to test these long-held beliefs through experimentation over the past five years. Their results have shown that P3 can form amyloid deposits at least as readily as amyloid beta and even more rapidly in some cases. These findings have been confirmed and expanded upon by an independent research group in the United Kingdom, which has begun exploring the relationship between P3 and amyloid beta, including how their interaction affects accumulation and toxicity. The long-held assumption that P3 is biologically harmless and irrelevant to Alzheimer's disease has been challenged by recent research findings. For decades, amyloid beta has dominated scientific explanations of Alzheimer's disease, but a prominent Alzheimer's researcher suggests that this narrow focus may be misguided. According to David Teplow, an emeritus professor of neurology at UCLA, the peptide has long been regarded as a central cause of the condition. However, his evaluation of new research indicates that scientists are beginning to reconsider this prevailing view. This reevaluation has significant implications for both basic science and clinical research into Alzheimer's disease, with far-reaching consequences for our understanding of the condition and its treatment options. Recent research suggests that Alzheimer's disease may be caused by more than just amyloid beta. By studying P3 and its interactions with other amyloid peptides, scientists hope to gain a better understanding of how brain cells are damaged. This reevaluation has significant implications for both basic science and clinical research into Alzheimer's disease, with far-reaching consequences for our understanding of the condition and its treatment options. A more complete picture of the processes involved could potentially lead to new directions in treatment, giving patients and their families renewed hope for a cure or effective management of the disease. --- Source: [ScienceDaily Health](https://www.sciencedaily.com/releases/2026/10/261013015838.htm) Published by Noti Group: https://noti.group/alzheimer-s-study-suggests-p3-may-be-contributing-factor/